Use of l-carnitine or derivatives thereof and antioxidants for the prevention and treatment of diseases elicited by oxidative stress to the nervous and cardiovascular system
CA 2200540 C · Owner: Sigma-Tau Industrie Farmaceutiche Riunite S.P.A · Inventors: Cavazza, Claudio
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Therapeutical use is described of L-carnitine some alkanoyl L-carnitines, and the pharmacologically acceptable salts thereof in combination with hydrophilic antioxidants or lipophilic antioxidants or derivatives thereof or natural products containing said substances for the prevention and treatment of deseases of the central nervous system such as parkinsonism trauma, cerebral palsy, diabetic neuropathy; of the peripheral nervous system such as diabetic peripheral neuropathy and traumatic nerve damage; of the cardiovascular system such as stroke ischaemic-reperfuson damage and intermittent claudication; and immune system abnormalities in conditions of low oxygen tension.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 20, 1997 and granted June 14, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 20, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 20, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.